NCT00996658 - Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone | Biotech Hunter

Enrollment

278

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

March 31, 2012

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Placebo

Placebo matching linagliptin tablets once daily

DRUG

Linagliptin

Linagliptin tablets once daily

Trial Locations (52)

Unknown

1218.61.01028 Boehringer Ingelheim Investigational Site, Escondido

1218.61.01014 Boehringer Ingelheim Investigational Site, Greenbrae

1218.61.01015 Boehringer Ingelheim Investigational Site, Los Angeles

1218.61.01042 Boehringer Ingelheim Investigational Site, Paramount

1218.61.01046 Boehringer Ingelheim Investigational Site, Poway

1218.61.01044 Boehringer Ingelheim Investigational Site, San Diego

1218.61.01009 Boehringer Ingelheim Investigational Site, Miami

1218.61.01049 Boehringer Ingelheim Investigational Site, Lawrenceville

1218.61.01008 Boehringer Ingelheim Investigational Site, Roswell

1218.61.01040 Boehringer Ingelheim Investigational Site, Meridian

1218.61.01016 Boehringer Ingelheim Investigational Site, Chicago

1218.61.01018 Boehringer Ingelheim Investigational Site, Chicago

1218.61.01048 Boehringer Ingelheim Investigational Site, Lafayette

1218.61.01001 Boehringer Ingelheim Investigational Site, Auburn

1218.61.01043 Boehringer Ingelheim Investigational Site, Olive Branch

1218.61.01052 Boehringer Ingelheim Investigational Site, Las Vegas

1218.61.01030 Boehringer Ingelheim Investigational Site, New York

1218.61.01007 Boehringer Ingelheim Investigational Site, Greensboro

1218.61.01004 Boehringer Ingelheim Investigational Site, Jacksonville

1218.61.01023 Boehringer Ingelheim Investigational Site, Wilmington

1218.61.01027 Boehringer Ingelheim Investigational Site, Perrysburg

1218.61.01031 Boehringer Ingelheim Investigational Site, East Providence

1218.61.01017 Boehringer Ingelheim Investigational Site, Simpsonville

1218.61.01005 Boehringer Ingelheim Investigational Site, Dallas

1218.61.01006 Boehringer Ingelheim Investigational Site, Houston

1218.61.01053 Boehringer Ingelheim Investigational Site, San Antonio

1218.61.01003 Boehringer Ingelheim Investigational Site, Sugar Land

1218.61.01024 Boehringer Ingelheim Investigational Site, Bennington

1218.61.01020 Boehringer Ingelheim Investigational Site, Spokane

1218.61.3301A Boehringer Ingelheim Investigational Site, Besançon

1218.61.3306A Boehringer Ingelheim Investigational Site, Béziers

1218.61.3311A Boehringer Ingelheim Investigational Site, Béziers

1218.61.3309A Boehringer Ingelheim Investigational Site, Bourg Des Cptes

1218.61.3310A Boehringer Ingelheim Investigational Site, Cournonterral

1218.61.3312A Boehringer Ingelheim Investigational Site, Laval

1218.61.3313A Boehringer Ingelheim Investigational Site, Louvigné-de-Bais

1218.61.3305A Boehringer Ingelheim Investigational Site, Paris

1218.61.3307A Boehringer Ingelheim Investigational Site, Paris

1218.61.91002 Boehringer Ingelheim Investigational Site, Bangalore

1218.61.91003 Boehringer Ingelheim Investigational Site, Bangalore

1218.61.91004 Boehringer Ingelheim Investigational Site, Bangalore

1218.61.91008 Boehringer Ingelheim Investigational Site, Hyderabad

1218.61.91009 Boehringer Ingelheim Investigational Site, Jaipur

1218.61.91010 Boehringer Ingelheim Investigational Site, Karnataka

1218.61.91001 Boehringer Ingelheim Investigational Site, Maharashtra

1218.61.91006 Boehringer Ingelheim Investigational Site, Maharashtra

1218.61.91011 Boehringer Ingelheim Investigational Site, Maharashtra

1218.61.91005 Boehringer Ingelheim Investigational Site, Mumbai

1218.61.91007 Boehringer Ingelheim Investigational Site, Mumbai

1218.61.63003 Boehringer Ingelheim Investigational Site, Cebu City

1218.61.63004 Boehringer Ingelheim Investigational Site, Cebu City

1218.61.63002 Boehringer Ingelheim Investigational Site, Davao City